Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 56.71M shares rose 58.9% year over year, ahead of the +24.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 9.2% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +58.9% holds above the trailing-twelve-month pace of +24.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.71M+9.2% QoQ
Last fiscal yearDec 2025
39.96M+17.8% YoY
LTMMar 2026
44.51M+24.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.9%——
1 year+17.8%——
3-year CAGR+27.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
39.96M USD
Year-over-year change
+17.8%

Weighted Avg Shares vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • EPRX.TO's LTM Mar 2026 weighted avg shares of 44.51M shares is the 5th highest of the 8 companies compared; the peer median is 75.7M shares.
  • Its year-over-year change of +24.9% is the 3rd highest of 8, against a peer median of +18.4%.
  • Over three fiscal years its annual growth of +27.5% compares with a peer median of +7.8%.
EPRX.TO Competitors Peer median
Weighted Avg Shares for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR
TSND.TOTerrAscend Corp.LTM Mar 2026305.61M +9.1%+7.2%
WEED.TOCanopy Growth CorporationLTM Mar 2026288.35M +167.7%+8.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026133.64M +18.4%—
HBP.TOHelix BioPharma Corp.LTM Apr 202675.7M +289.1%+23.1%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 202644.51M +24.9%+27.5%
PRN.TOProfound Medical Corp.LTM Mar 202631.8M +21.4%+13.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 202630.27M +10.4%+2.8%
DR.TOMedical Facilities CorporationLTM Mar 202618.7M -3.7%-12.8%
Peer median (excluding EPRX.TO) 75.7M+18.4%+7.8%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue111.53K193.27K158.05K163.47K241.88K
Gross Profit(111.53K)(193.27K)(158.05K)(163.47K)(241.88K)
Gross Margin—————
Research & Development10.17M17.58M21M15.17M21.51M
Selling, General & Admin8.2M5.81M7.37M10.92M17.1M
Operating Expenses18.38M23.38M28.37M25.54M38.86M
Depreciation & Amortization111.53K193.27K158.05K163.47K241.88K
EBITDA(21.96M)(22.14M)(28.16M)(23.43M)(38.86M)
EBITDA Margin—————
Operating Income(18.47M)(23.58M)(27.78M)(25.71M)(39.11M)
Operating Margin—————
Interest Income65.73K569.32K876.96K1.1M1.44M
Interest Expense1.3M1.59M1.19M913.1K0
Other Income / Expenses(4.9M)(341.09K)(1.08M)1.2M(155.19K)
Income Before Tax(23.37M)(23.92M)(28.93M)(24.51M)(39.26M)
Pre-Tax Margin—————
Income Tax Expense00(67.51K)1.72K19.42K
Net Income(22.99M)(23.26M)(28.15M)(24.28M)(39.25M)
Net Margin—————
EPS (Basic)(1.61)(1.21)(1.19)(0.72)(1.05)
EPS (Diluted)(1.61)(1.21)(1.19)(0.72)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.